• CCG-1423: A RhoA Inhibitor Transforming Cell Barrier Researc

  2026-08-01

  CCG-1423, a selective RhoA inhibitor from APExBIO, streamlines advanced workflows for dissecting cell barrier disruption and apoptotic signaling in cancer and viral studies. Its unique mechanism—targeting MRTF-A import—enables researchers to precisely interrogate RhoA/ROCK-mediated events underpinning cell permeability and invasive behavior.

• MSH2 Loss Drives Cisplatin Resistance in Muscle-Invasive Bla

  2026-07-31

  A recent whole-genome CRISPR screen identified MSH2 as a key mediator of cisplatin resistance in muscle-invasive bladder cancer. The findings suggest that MSH2 protein level may serve as a predictive biomarker for platinum-based chemotherapeutic response, with important implications for patient stratification and future therapy design.

• HotStart Universal 2X Green qPCR Master Mix: Precision in Ge

  2026-07-31

  HotStart™ Universal 2X Green qPCR Master Mix empowers researchers with robust, reproducible gene expression quantification—combining hot-start Taq polymerase specificity, universal ROX compatibility, and real-time detection. Optimized for challenging workflows and melt curve-based specificity assessment, this APExBIO solution elevates molecular research from bench to clinical translation.

• Zosuquidar (LY335979) 3HCl: Redefining MDR Reversal in Oncol

  2026-07-30

  Explore how Zosuquidar (LY335979) 3HCl advances multidrug resistance (MDR) research by targeting P-glycoprotein in cancer. This article uniquely bridges clinical insight, mechanistic depth, and assay optimization, providing new perspectives beyond existing literature.

• Mutational Landscape of Myeloma Cell Lines: Pathways and Dru

  2026-07-30

  This article highlights a comprehensive exome-wide analysis of 30 human multiple myeloma cell lines, revealing key driver mutations and pathway alterations linked to tumor progression and drug resistance. The findings serve as a foundation for targeted research and model selection in hematological malignancy studies, with direct implications for assay design and drug development.

• Tiamulin (Thiamutilin): Deep Mechanistic Insights and Ionoph

  2026-07-29

  Explore the molecular mechanisms of Tiamulin (Thiamutilin), a leading veterinary antibiotic, with a focus on its unique synergy and risks when combined with ionophores. This article delivers advanced guidance for researchers and veterinarians seeking evidence-based, practical strategies beyond standard assay protocols.

• IDO1 Inhibition Drives STAT3 Activation and Tumor Protection

  2026-07-29

  This study reveals that inhibition of indoleamine 2,3-dioxygenase 1 (IDO1) unexpectedly promotes tumor-intrinsic STAT3 pathway activation, leading to enhanced tumor cell survival despite immune activation. The work highlights the need to co-target the IL-6/JAK2/STAT3 axis to counteract adverse protective effects in cancer immunotherapy.

• Scenario-Driven Best Practices for Parathyroid hormone (1-34

  2026-07-28

  This article delivers actionable, scenario-based guidance for deploying Parathyroid hormone (1-34) (human) (SKU A1129) in cell viability, proliferation, and calcium regulation workflows. Drawing on peer-reviewed evidence and real-world lab needs, it demonstrates how this PTH (1-34) peptide fragment from APExBIO provides reproducible, high-sensitivity results in bone metabolism and kidney disease research.

• Dasatinib Monohydrate (BMS-354825): Precision Kinase Inhibit

  2026-07-28

  Dasatinib Monohydrate (BMS-354825) is a multitargeted kinase inhibitor with nanomolar potency against ABL, SRC, and imatinib-resistant BCR-ABL. It is FDA-approved for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, with robust preclinical and clinical benchmarks supporting its use. The compound’s stability and solubility profile enable rigorous translational research workflows.

• Refined Jiawei-Xiaoyao Pill Formula Rapidly Reverses LPS-Ind

  2026-07-27

  This study identifies and characterizes a simplified, three-herb derivative (GMA) of the Jiawei-Xiaoyao Pill that exerts rapid antidepressant-like effects in an LPS-induced mouse model of depression. The findings reveal that GMA achieves these effects by simultaneously reducing neuroinflammation and restoring neuroplasticity signaling, with implications for optimizing herbal antidepressant therapies and mechanistic investigations in neuropsychiatric research.

• HyperScript RT SuperMix for qPCR: Precision in NAFLD Gene Ex

  2026-07-27

  Explore how HyperScript RT SuperMix for qPCR enables precise gene expression analysis in challenging models like NAFLD, offering unmatched performance for reverse transcription of complex RNA. Discover unique, evidence-driven assay strategies and practical insights.

• A40926: Dalbavancin Precursor Powering Next-Gen Antibacteria

  2026-07-26

  A40926, the natural glycopeptide antibiotic and direct precursor to dalbavancin, empowers high-sensitivity research workflows targeting Gram-positive and multidrug-resistant pathogens. This article delivers actionable protocols, troubleshooting guidance, and a translational lens on the latest biosynthetic and regulatory insights—driving reproducibility and innovation in antibiotic development.

• Endothelial SGK1 Drives Salt-Induced Vascular Stiffening

  2026-07-25

  Zhang et al. reveal that endothelial SGK1 activity is a key driver of vascular stiffening in salt-sensitive settings, acting through actin polymerization and sodium channel regulation. Their work combines genetic and pharmacological approaches—utilizing the SGK1 inhibitor EMD638683—to clarify mechanisms underlying cardiovascular risk, providing a mechanistic foundation for further translational research.

• Pomalidomide (CC-4047): Precision Tools for Myeloma Genomic

  2026-07-24

  Explore how Pomalidomide (CC-4047) enables advanced insights into mutational heterogeneity and functional assays in multiple myeloma research. Uncover application strategies and protocol optimizations grounded in recent genomic discoveries.

• High Viscosity in Tumors Drives P-gp-Mediated Chemoresistanc

  2026-07-24

  This study uncovers how elevated extracellular fluid viscosity in the tumor microenvironment induces chemoresistance by upregulating P-glycoprotein (P-gp) via mechanosensitive signaling. The findings provide mechanistic insight into tumor physical properties and suggest new experimental and therapeutic directions for overcoming drug resistance.

446 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page